Exchange: NASDAQ·Updated 07:55 PM EDT

CRSP News

News
all
press releases
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
Zacks
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
Zacks
More News
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks
CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
Zacks
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
Where Will CRISPR Therapeutics Stock Be in 2030?
Key PointsCRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term...
Nasdaq News: Markets
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
Zacks
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.
Zacks
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
Zacks
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Roche advances vamikibart toward potential US approval after phase III trials show sustained vision improvements, reduced retreatment needs and a favorable safety profile.
Zacks
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks

Advertisement|Remove ads.